Literature DB >> 21077734

Saccharomyces boulardii and Candida albicans experimental colonization of the murine gut.

G Samonis1, M E Falagas, S Lionakis, M Ntaoukakis, D P Kofteridis, I Ntalas, S Maraki.   

Abstract

Saccharomyces boulardii has been and continues to be extensively used as a probiotic, with only rare associations with fungemia. This study evaluated the virulence of this yeast when given as a probiotic, and its role in preventing gastrointestinal (GI) colonization by Candida. Adult male Crl:CD1 (ICR) BR mice were given S. boulardii orally in three different doses or normal saline for 14 days. Stool cultures were performed at the time of discontinuation of yeast administration, as well as 1 and 2 weeks later. Gut colonization was proportional to the given dose but lasted only 1 week and no dissemination of the yeast was detected. S. boulardii was also given for 2 and 4 weeks to mice fed chow containing Candida albicans. S. boulardii in the gut did not affect Candida GI colonization. These findings suggest that oral administration of S. boulardii induces a substantial but short term increase of this yeast in the intestinal lumen and administration of the probiotic does not prevent subsequent GI colonization by C. albicans.

Entities:  

Mesh:

Year:  2010        PMID: 21077734     DOI: 10.3109/13693786.2010.533203

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  6 in total

Review 1.  Mycobiota in gastrointestinal diseases.

Authors:  Pranab K Mukherjee; Boualem Sendid; Gautier Hoarau; Jean-Frédéric Colombel; Daniel Poulain; Mahmoud A Ghannoum
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2014-11-11       Impact factor: 46.802

2.  Prophylactic Saccharomyces boulardii versus nystatin for the prevention of fungal colonization and invasive fungal infection in premature infants.

Authors:  Gamze Demirel; Istemi Han Celik; Omer Erdeve; Sibel Saygan; Ugur Dilmen; Fuat Emre Canpolat
Journal:  Eur J Pediatr       Date:  2013-05-24       Impact factor: 3.183

3.  Strain engineering and metabolic flux analysis of a probiotic yeast Saccharomyces boulardii for metabolizing L-fucose, a mammalian mucin component.

Authors:  Jungyeon Kim; Yu Eun Cheong; Sora Yu; Yong-Su Jin; Kyoung Heon Kim
Journal:  Microb Cell Fact       Date:  2022-10-07       Impact factor: 6.352

4.  Modulation of intestinal inflammation by yeasts and cell wall extracts: strain dependence and unexpected anti-inflammatory role of glucan fractions.

Authors:  Samir Jawhara; Khalid Habib; François Maggiotto; Georges Pignede; Pascal Vandekerckove; Emmanuel Maes; Laurent Dubuquoy; Thierry Fontaine; Yann Guerardel; Daniel Poulain
Journal:  PLoS One       Date:  2012-07-27       Impact factor: 3.240

5.  Pathogenic potential of Saccharomyces strains isolated from dietary supplements.

Authors:  Silvia Llopis; Carolina Hernández-Haro; Lucía Monteoliva; Amparo Querol; María Molina; María T Fernández-Espinar
Journal:  PLoS One       Date:  2014-05-30       Impact factor: 3.240

6.  Evaluation of Microbiome Alterations Following Consumption of BIOHM, a Novel Probiotic.

Authors:  Mahmoud A Ghannoum; Thomas S McCormick; Mauricio Retuerto; Gurkan Bebek; Susan Cousineau; Lynn Hartman; Charles Barth; Kory Schrom
Journal:  Curr Issues Mol Biol       Date:  2021-11-29       Impact factor: 2.976

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.